22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · May 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated July 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese PopulationSemaglutide
Endocrinology, diabetes & metabolism15 July 2026Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver TransplantationSemaglutide
ACG case reports journal15 July 2026Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription recordsSemaglutide
Biology methods & protocols15 July 2026Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysisSemaglutide
The Journal of international medical research15 July 2026Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative ReviewSemaglutide
Journal of diabetes15 July 2026Off-label GLP-1 receptor agonist and tirzepatide use for weight loss: patient safety and regulatory oversightTirzepatide
Annals of medicine and surgery (2012)15 July 2026Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantationTirzepatide
Frontiers in endocrinology15 July 2026Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failureTirzepatide
Diabetes & vascular disease research15 July 2026Medical Treatments for Obesity: What Does the Future Have in Store?Retatrutide
J Clin Endocrinol Metab14 July 2026Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy miceSemaglutide
Molecular Brain11 July 2026The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac CatheterizationSemaglutide
American Journal of Cardiology11 July 2026Direct effects of glucagon-like peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: a systematic review and meta-analysisSemaglutide
Metabolism Open11 July 2026TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity MedicationsSemaglutide
Handbook of Experimental Pharmacology11 July 2026Pharmacologic Treatment for Obstructive Sleep Apnea in Older AdultsSemaglutide
Drugs & Aging11 July 2026Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: PERCEPTIONS survey resultsTirzepatide
Obesity Pillars11 July 2026Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetesTirzepatide
Osteoporosis International11 July 2026Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trialTirzepatide
Current Medical Research and Opinion11 July 2026Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technologyTB-500
Exp Eye Res10 July 2026Imaging in Semaglutide StudySemaglutide
ClinicalTrials.gov10 July 2026Influence without medical expertise: a social network analysis of Mounjaro discussions on XTirzepatide
Saudi Pharmaceutical Journal10 July 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.